Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
Int J Mol Sci. 2023 Sep 30;24(19):14800. doi: 10.3390/ijms241914800.
Since the emergence of the coronavirus disease 2019 (COVID-19) pandemic, many lives have been tragically lost to severe infections. The COVID-19 impact extends beyond the respiratory system, affecting various organs and functions. In severe cases, it can progress to acute respiratory distress syndrome (ARDS) and multi-organ failure, often fueled by an excessive immune response known as a cytokine storm. Mesenchymal stem cells (MSCs) have considerable potential because they can mitigate inflammation, modulate immune responses, and promote tissue regeneration. Accumulating evidence underscores the efficacy and safety of MSCs in treating severe COVID-19 and ARDS. Nonetheless, critical aspects, such as optimal routes of MSC administration, appropriate dosage, treatment intervals, management of extrapulmonary complications, and potential pediatric applications, warrant further exploration. These research avenues hold promise for enriching our understanding and refining the application of MSCs in confronting the multifaceted challenges posed by COVID-19.
自 2019 年冠状病毒病（COVID-19）大流行以来，许多人因严重感染而不幸丧生。COVID-19 的影响不仅限于呼吸系统，还会影响到各种器官和功能。在严重的情况下，它可能会发展为急性呼吸窘迫综合征（ARDS）和多器官衰竭，通常是由称为细胞因子风暴的过度免疫反应引起的。间充质干细胞（MSCs）具有很大的潜力，因为它们可以减轻炎症、调节免疫反应和促进组织再生。越来越多的证据表明 MSCs 治疗严重 COVID-19 和 ARDS 的疗效和安全性。然而，仍有一些关键方面需要进一步探讨，如 MSC 给药的最佳途径、合适的剂量、治疗间隔、肺外并发症的管理以及潜在的儿科应用。这些研究途径有望丰富我们对 MSCs 的认识，并完善其在应对 COVID-19 多方面挑战中的应用。
